CCN1, a Pro-Inflammatory Factor, Aggravates Psoriasis Skin Lesions by Promoting Keratinocyte Activation  by Sun, Yue et al.
CCN1, a Pro-Inﬂammatory Factor, Aggravates
Psoriasis Skin Lesions by Promoting Keratinocyte
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Huidan Li1, Tianhang Zhai1, Baihua Shen1, Xiangdong Chen2 and Ningli Li1
Psoriasis is a common chronic skin disease characterized by epidermal hyperplasia and inﬂammation.
The pathogenesis of psoriasis is multifactorial and is not fully understood. Here we demonstrate that CCN1
(also called Cyr61, which is short for cysteine-rich 61), an extracellular matrix protein that is also considered a
pro-inﬂammatory factor, is highly expressed in the lesional skin of psoriasis patients, as well as in that of
imiquimod (IMQ)- and IL-23-treated psoriasis-like mice. Then we show that blocking CCN1 function in vivo
attenuates epidermal hyperplasia and inﬂammation in psoriasis-like mice. Further, in primary cultured normal
human keratinocytes and HaCaT (human keratinocyte cell line) cells, CCN1 promotes keratinocyte activation,
including the proliferation and expression of immune-related molecules. Finally, we observe that integrin α6β1 is
the receptor of CCN1 in keratinocytes, and CCN1 stimulation activates the downstream phosphoinositide-3
kinase/Akt/NF-κB signaling pathway. Taken together, our ﬁndings reveal that CCN1 has a critical role in psoriasis
pathogenesis. Moreover, as CCN1 is a secreted extracellular matrix (ECM) protein, our study also provides
evidence that ECM, which is involved in psoriatic pathogenesis, could be a potent target for psoriasis treatment.
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INTRODUCTION
Psoriasis is a common immune-mediated inﬂammatory
disease characterized by epidermal hyperplasia and inﬂam-
mation, the main pathogeneses of psoriasis (Lowes et al.,
2007; Perera et al., 2012). As a chronic relapsing and
remitting inﬂammatory skin and joint disease, it affects 2–3%
of the population worldwide (Christophers, 2001; Nestle
et al., 2009). The typical skin lesion induced by epidermal
hyperplasia and inﬂammation associated with psoriasis
vulgaris is characterized by redness, thickness, and scaling,
which severely impairs the patient’s quality of life (Perera
et al., 2012). Although the pathogenesis is unclear, epidermal
hyperplasia mediated by epidermal cell activation is a key
pathological process during psoriasis development. In psoriasis,
keratinocytes are activated and deviate from the normal
differentiation cycle, leading to the excessive proliferation and
expression of immune-related molecules, primarily ICAM, HLA-
ABC, and HLA-DR (Lowes et al., 2007; Laggner et al., 2011;
Perera et al., 2012). Thus keratinocyte activation results in major
histological features of psoriasis, including epidermal hyper-
plasia, parakeratosis, and skin inﬂammation.
Extracellular matrix (ECM), the extracellular part of the
multicellular structure, typically provides structural and bio-
chemical support to the surrounding cells (Michel et al., 2010).
As a secreted extracellular matrix protein, CCN1 (Cyr61) is
encoded by an immediate early gene; it has a role in mediating
cell adhesion and in inducing cell migration, which is closely
related to cell proliferation, neovascularization, and tumor
formation (Tsai et al., 2000; Grzeszkiewicz et al., 2001; Mo
et al., 2002; Holloway et al., 2005; Lin et al., 2007; Meng et al.,
2012).
CCN1 expression is regulated by the amount of certain
agents, including cytokines, growth factors, hormone, and
some drugs. It has been reported that IL-17 enhances CCN1
production in ﬁbroblast-like synoviocytes; tumor necrosis
factor (TNF)-α and IL-1β increase CCN1 production in human
osteoblasts; and epidermal growth factor promotes CCN1
expression in human endometrial epithelial cells (Zhang et al.,
2009; Kok et al., 2011; Klein et al., 2012).
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Further, accumulating research has indicated that CCN1
acts as a pro-inﬂammatory factor in the development of
inﬂammatory and autoimmune diseases by enhancing the
production of cytokines such as TNF-α, IL-6, and IL-8 in vivo
and in vitro (Bai et al., 2010; Lin et al., 2012; Zhu et al., 2013).
However, it is unknown whether CCN1 has a role in the
pathogenesis of psoriasis.
In the current study, we found that the expression of CCN1
was upregulated in skin lesions typical of psoriasis, as well as in
that of imiquimod (IMQ)-induced and IL-23-induced psoriasis-
like mice. An in vivo study revealed that blocking CCN1
expression with lentiviral vectors expressing short hairpin RNA
(shRNA) and a neutralizing CCN1 monoclonal antibody could
ameliorate epidermal hyperplasia and inﬂammation in
psoriasis-like mice. Mechanistically, we showed that CCN1
induced the proliferation of normal human keratinocytes and
the keratinocyte cell line HaCaT, as well as the expression of
ICAM, HLA-ABC, and HLA-DR through the α6β1/phosphoino-
sitide-3 kinase (PI3K)/Akt/NF-κB pathway. Our results revealed
that CCN1 has a critical role in the pathogenesis of psoriasis,
thereby supplying evidence that ECM CCN1 is involved in the
development of psoriasis. Thus targeting CCN1 may represent
a potent strategy in psoriasis treatment.
RESULTS
CCN1 is overexpressed in the epidermis of human psoriatic skin
To explore whether CCN1 is involved in the pathogenesis of
psoriasis, we examined the expression of CCN1 in skin
samples obtained from psoriasis patients and normal donors.
The results showed that mRNA and protein expression of
CCN1 increased signiﬁcantly in the lesional and non-lesional
skin of psoriasis patients (Figure 1a); however, in normal
donors, CCN1 mRNA levels were low (Figure 1a), and the
protein expression was barely detectable (data not shown).
Moreover, CCN1 expression was detected in separated
epidermis and dermis tissue of non-lesional and lesional skin
samples from psoriasis patients by western blotting analysis.
The results showed that, in the epidermis of psoriasis patients,
CCN1 expression was increased signiﬁcantly in lesional tissue
(Figure 1b, left panel), whereas in the dermis CCN1
expression was lower compared with that in the epidermis
(Figure 1b, right panel). Immunohistochemistry revealed that
CCN1 was barely detected in normal epidermis; in non-
lesional skin CCN1 was slightly expressed, and in lesional
skin CCN1 was overexpressed in thickened epidermis and in
downward extended epidermal rete ridges (Figure 1c). Taken
together, our results indicate that CCN1 is overexpressed in
the lesional skin of patients with psoriasis.
Knockdown of CCN1 expression ameliorates skin lesions in
IMQ-induced psoriasis-like mice
Given that increased CCN1 expression was found in human
psoriasis skin lesions, we are committed to discussing its role
in the pathogenesis of psoriasis. First, we established a
psoriasis-like skin disorder in BALB/c mice using IMQ
treatment, according to previous reports (van der Fits et al.,
2009; Van Belle et al., 2012). Then, we detected the CCN1
expression proﬁle in the IMQ-treated mice. Using real-time
PCR and western blotting analysis, we found that CCN1
expression in the back skins of IMQ-treated mice was
signiﬁcantly upregulated (Figure 2a). Further, the immuno-
ﬂuorescence staining showed that increased CCN1 expres-
sion occurred primarily in the epidermis (Figure 2b).
To verify the role of CCN1 in skin lesion formation, we used
lentiviral vector expressing shRNA to knock down CCN1
expression in the back skin of IMQ-treated mice, according to
previous reports (Watson et al., 2002; Rubinson et al., 2003).
The scheme of the shRNA-expressing vector and the sequence
of the designed shRNA targeting CCN1 mRNA are shown in
Supplementary Figure S1a online. Before inducing a psoriasis-
like skin disorder in mice, we injected 5×106 lentiviruses
(100 μl) intracutaneously into the back skin of mice. After
3 days, skin cells were infected with lentiviruses, as shown by
the green ﬂuorescent protein expression (Supplementary Figure
S1b online). Compared with control viruses, the viruses
knocking down the CCN1 expression signiﬁcantly reduced
the CCN1 expression (Supplementary Figure S1c online). In
CCN1-knockdown mice, hematoxylin and eosin staining of
sections of the back skin showed that epidermal hyperplasia
was improved dramatically, epidermal thickness was
decreased, and the number of inﬁltrated inﬂammatory cells
in the dermis was reduced (Figure 2c–e). Further, the
expression of typical cytokines TNF-α and IL-17 in psoriasis
was reduced signiﬁcantly (Figure 2f). These results suggest that
CCN1 has an important role in the development of skin lesions
in psoriasis.
Knockdown of CCN1 activation reduces epidermal hyperplasia
and inﬂammation in IL-23-induced psoriasis-like skin lesions
To conﬁrm these results, we also established an IL-23-induced
psoriasis-like mouse model, according to previous reports
(Chan et al., 2006; Rizzo et al., 2011), and we examined
CCN1 expression in this mouse model. The real-time PCR and
immunohistochemistry staining results revealed that the level
of CCN1 was elevated in IL-23-induced skin lesions (Figure
3a and b).
Thereafter, using the lentiviral vector, we knocked down
the CCN1 expression in the skin of IL-23-treated mice.
Compared with control mice, the ears of the CCN1-
knockdown mice did not swell signiﬁcantly (Figure 3d).
Histopathology indicated that the downward extended
epidermal rete ridges, epidermal thickness, and the number
of inﬁltrated inﬂammatory cells in the dermis were noticeably
reduced in pLVX-iCCN1-injected mice (Figure 3e–g). Mean-
while, the expression of inﬂammatory cytokines TNF-α and
IL-17 was signiﬁcantly decreased after knocking down the
CCN1 expression (Figure 3h). These data suggest that
blocking CCN1 expression reduces epidermal hyperplasia
and inﬂammation in the skin lesions of IL-23-induced
psoriasis-like mice, indicating that CCN1 indeed aggravates
lesional psoriatic skin in vivo.
Neutralization of CCN1 decreased skin lesion and inﬂammation
in psoriasis mice
As CCN1 is involved in the activation of keratinocytes, we
questioned whether CCN1 will be a potential target for
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psoriasis treatment. We treated IMQ-induced psoriasis-like
mice with CCN1 neutralization antibody 093G9 (Lin et al.,
2012; Meng et al., 2012). Considering the circulation and
metabolism of the antibody in vivo and to develop the
antibody’s fullest potential, we treated the mice with 093G9
up to the sixteenth day of IMQ application. The results
showed that CCN1 expression in the skin of psoriasis-like
mice treated with 093G9 was signiﬁcantly inhibited
(Figure 4a). This ﬁnding may be attributed to the autocrine
expression of CCN1 and the positive feedback regulation. As
to the psoriasis-like symptoms, histopathology revealed that
the downward extended epidermal rete ridges (Figure 4b) and
epidermal thickness, and the number of inﬁltrated inﬂamma-
tory cells in the dermis were noticeably reduced in 093G9-
treated mice (Figure 4b–d). Meanwhile, the expression
of inﬂammatory cytokines such as TNF-α and IL-17 was
signiﬁcantly decreased (Figure 4e). These data suggest that
blocking CCN1 reduces epidermal hyperplasia and inﬂam-
mation in skin lesions in vivo. These results also suggest that
CCN1 indeed has an important role in the development of
skin lesions in psoriasis and might be a potential treatment
strategy for psoriasis.
CCN1 induces the activation of keratinocytes
We found that CCN1 is highly expressed in psoriatic skin
lesions, and knockdown of CCN1 expression ameliorates
psoriasis symptoms in psoriasis-like mice; therefore, we
explored the role of CCN1 in psoriasis development. It is
known that, in psoriasis development, keratinocyte activation
is critical and characterized by the over-proliferation and
overexpression of immunological molecules (Terui et al.,
1987; Homey et al., 2000; Lowes et al., 2007; Perera et al.,
2012). Thus we examined the effect of CCN1 on keratinocytes
using primary cultured human epidermal keratinocytes. First,
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Figure 1. CCN1 expression is increased in the skin samples from psoriasis patients. (a) CCN1 expression was evaluated with real-time PCR (left panel) and
western blotting analysis (right panel) of the skin biopsies isolated from psoriasis patients and healthy donors. Each point represents a skin sample obtained from a
healthy donor (○), non-lesional skin (●), or corresponding lesional skin of one psoriasis patient (▲). (b) CCN1 expression in separated epidermis and dermis,
respectively, detected in non-lesional and lesional skin samples from psoriasis patients treated with dispase (50 Uml−1) at 4 °C overnight. (c) Representative
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means± SD.*Po0.05, **Po0.01.
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we added CCN1 into the culture and found that CCN1
promoted keratinocyte proliferation in a dose-dependent
manner. Note that 5 μgml−1 of CCN1 was the optimal dose
detected by a CCK8 (Cell Counting Kit 8) assay (a methyl
thiazolyl tetrazolium-type-like assay) (Figure 5a). Further, we
used 5 μgml−1 of CCN1 to examine the keratinocyte
proliferation using Ki67 staining. We found that the frequency
and mean ﬂuorescence intensity of Ki67+ cells increased
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Figure 2. CCN1 expression knocked down by lentiviral vector ameliorates psoriasis symptoms in imiquimod (IMQ)-induced psoriasis-like mice. (a) CCN1
expression in the back skins of control and IMQ-treated mice detected by real-time PCR and western blotting. Each point represents a skin sample obtained from
control (○) or IMQ-treated (●) mice. (b) Representative immunoﬂuorescent staining of CCN1 in the back skins of control and IMQ-treated mice. Bar=20 μm.
(c) Representative histological sections of the skins infected with control viruses and CCN1-targeting viruses examined by hematoxylin and eosin staining.
Bar=100 μm. (d) Epidermal thickness and (e) inﬁltrated cells in the dermis were measured from the back skins of mice. (f) Expression of tumor necrosis factor
(TNF)-α and IL-17 in the back skins examined by real-time PCR. For d–f, each point represents a skin sample obtained from pLV-iCon virus-treated (○) or pLV-
iCCN1 virus-treated (●) mice. *Po0.05, **Po0.01, ***Po0.001. The data represent one of three independent experiments. DAPI, 4,6-diamidino-2-phenylindole.
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remarkably (Figure 5b). In addition, using the carboxyﬂuor-
escein succinimidyl ester staining technique, we found that
CCN1 provoked keratinocyte division (Figure 5c), indicating
that CCN1 indeed promoted keratinocyte proliferation.
Next, we examined the altered activation marker proﬁles,
which are also immune-related molecules, expressed on the
surface of keratinocytes (Terui et al., 1987; Lowes et al., 2007;
Perera et al., 2012). The results showed that the frequency and
mean ﬂuorescence intensity of ICAM+, HLA-ABC+, or HLA-
DR+ cells were increased on primary cultured keratinocytes
(Figure 5d). Consistently, the mRNA expression of ICAM,
HLA-ABC, and HLA-DR was elevated by CCN1 (Figure 5e).
Moreover, we also examined these responses on CCN1-
stimulated HaCaT cells (a human keratinocyte cell line).
Consistent with the results in primary cultured keratinocytes,
Cry61 increased HaCaT cell activation, including the
proliferation and expression of immune-related molecules
(data not shown). Taken together, our data suggest that CCN1
promotes excessive activation of keratinocytes, which is
important in the pathogenesis of psoriasis.
CCN1 activates the α6β1/PI3K/Akt/NF-κB signaling pathway
It is well documented that in different types of cells CCN1
receptors comprise different integrin subunits. These subunits
include α1–6, αv, αm, and β1–6 (Chen et al., 2000, 2001;
Grzeszkiewicz et al., 2001; Mo et al., 2002; Lin et al., 2012).
In this study, we identiﬁed a CCN1-related integrin proﬁle in
the CCN1-stimulated keratinocytes and skin samples from
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Figure 3. CCN1 expression knocked down by lentiviral vector relieves psoriasis symptoms in IL-23-treated mice. (a) CCN1 expression in ear skins of control (○)
and IL-23-challenged (●) mice detected by real-time PCR. (b) Representative immunohistochemical staining of CCN1 expression in the ear skins of control and
IL-23-challenged mice. Bar=50 μm. (c) CCN1 expression in virus-treated ear skins detected by real-time PCR. (d) Ear thickness of virus-treated mice. (e)
Representative histological sections of ear skins examined by hematoxylin and eosin staining. Bar=100 μm. (f) Epidermal thickness and (g) inﬁltrated cells in the
dermis were measured in the ear skins of virus-treated mice. (h) Expression of tumor necrosis factor (TNF)-α and IL-17 in ear skins examined by real-time PCR. For
c, d, f–h, each point represents a skin sample obtained from pLV-iCon virus-treated (○) or pLV-iCCN1 virus-treated (●) mice. *Po0.05, **Po0.01. The data
represent one of three independent experiments.
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donors. The results showed that, in CCN1-stimulated primary
cultured keratinocyte cells, the expression of β1 was
signiﬁcantly increased (Figure 6a), and in the lesional skin
of patients the expression of α6 and β1 subunits was elevated
signiﬁcantly (Figure 6b), suggesting that α6β1 is the major
integrin receptor in keratinocytes. To determine whether α6β1
is a receptor of CCN1, we further knocked down α6β1 by
speciﬁc siRNA and examined the expression of immune-
related molecules. As shown in Figure 6c, knocking down
α6β1 impaired CCN1-induced ICAM production. These results
indicated that α6β1 is a major receptor of CCN1 in
keratinocytes.
Thereafter, we examined the activation of signaling path-
ways downstream of integrin α6β1. The results showed that
when CCN1 was added to the HaCaT cell culture system the
phosphorylation of PI3K, Akt, and NF-κB p65 increased
remarkably (Figure 6d). Further, using immunoﬂuorescence
staining, we found that CCN1 indeed induced NF-κB
translocation into the nucleus of keratinocytes (Figure 6e).
These results indicated that CCN1 activates the α6β1/PI3K/Akt/
NF-κB signaling pathway in keratinocytes.
DISCUSSION
It has been demonstrated that CCN1 is a pro-inﬂammatory
factor (Bai et al., 2010; Jun and Lau, 2011; Lin et al., 2012). In
rheumatoid arthritis, CCN1 promotes synovium hyperplasia
by enhancing the over-proliferation of ﬁbroblast-like syno-
viocytes, which in turn stimulates inﬂammation by promoting
T heler type 17 and neutrophil activity (Zhang et al., 2009; Lin
et al., 2012). In this study, we found that CCN1 was
upregulated in the lesional skin of psoriasis patients and
IMQ- and IL-23-induced psoriasis-like mice. Knocking down
CCN1 expression using shRNA-expressing lentivirus vector
and neutralizing antibody in vivo reduced the epidermal
hyperplasia and inﬂammation associated with psoriasis. In
vitro experiments demonstrated the promoting role that CCN1
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had in keratinocyte activation through the α6β1/PI3K/Akt/NF-
κB pathway. These results revealed that CCN1 is closely
linked to psoriatic skin lesions by promoting keratinocyte
activation.
Note that various inﬂammatory cytokines (e.g., TNF, IFN-γ,
and IL-17) induce keratinocyte activation (Lowes et al., 2007;
Perera et al., 2012). It has been demonstrated that ECM is
involved in maintaining an inﬂammatory microenvironment
for some diseases, and previous studies have shown that
targeting ECM protein might present multiple therapeutic
opportunities (Padmanabhan and Gonzalez, 2012). However,
it remains unknown whether the ECM protein has a role in the
pathology of psoriasis. CCN1 is an ECM protein, acting as a
pro-inﬂammatory factor to maintain the inﬂammatory micro-
environment by supplying TNF-α, IL-6, and IL-8 in auto-
immune diseases, such as rheumatoid arthritis (Lin et al., 2012;
Zhu et al., 2013). In this study, we found that CCN1 expression
was elevated in the lesional skin of psoriasis patients.
Apart from lesional skin, we found that CCN1 expression is
higher in the non-lesional skin of psoriasis patients compared
with the skin of healthy individuals (Figure 1a, Po0.01). On
the basis of the role of CCN1 in keratinocyte activation, it can
be said that the overexpression of CCN1 might be associated
with the spread of skin lesions and illness relapse. Moreover,
considering that CCN1 contributes to synovium hyperplasia
in rheumatoid arthritis development (Zhang et al., 2009) and
epidermal hyperplasia in psoriasis pathogenesis, our ﬁnding
in the current study suggests that CCN1 might be involved in
the pathology of psoriatic arthritis.
As keratinocyte activation contributes to epidermal hyper-
plasia and parakeratosis in psoriasis (Gottlieb et al., 1986;
Paukkonen et al., 1995; Kok et al., 2013), we proposed that
CCN1 drove the proliferation and expression of HLA-ABC,
HLA-DR, and ICAM in primary cultured human keratinocytes
in vitro. These molecules enhance the auto-antigenicity of
keratinocytes, and mediate leukocyte–keratinocyte interac-
tions, thereby aggravating skin inﬂammation (Kaudewitz
et al., 1985). Considering that CCN1 expression was
upregulated by inﬂammatory cytokines such as TNF-α and
IL-17 (Gashaw et al., 2008; Zhang et al., 2009), CCN1 acts as
a link in keratinocyte activation and skin inﬂammation,
promoting the formation of a feed-forward and vicious cycle
in psoriasis pathogenesis. Blocking CCN1 with a speciﬁc
antibody or interfering with CCN1 in vivo could reduce CCN1
expression and impede the vicious cycle, thus alleviating the
symptoms of psoriasis.
Previous studies have reported that the integrin molecules
α1–6, αv, αm, and β1–6 consist of multiple receptors of CCN1
expressed in different types of cells (Chen et al., 2000, 2001;
Grzeszkiewicz et al., 2001; Mo et al., 2002; Harper et al.,
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2009; Lin et al., 2012). However, the CCN1 receptor in
keratinocytes is still unknown. Our results showed that,
among the candidate receptors for CCN1, the expression of
α6 and β1 was high in keratinocytes and lesional skins from
psoriasis patients, and the knockdown of α6β1 expression
resulted in impaired ICAM expression stimulated by CCN1.
Thus we determined that α6β1 was the receptor of CCN1 in
human keratinocytes. It has been reported that PI3K/Akt/NF-
κB acts as a signal transduction pathway for CCN1/integrin
stimulation (Chen and Du, 2007). Our further analysis
indicated that CCN1 treatment of keratinocytes led to the
activation of PI3K, Akt, and NF-κB.
Because CCN1 is a secreted ECM protein, we used a
speciﬁc antibody to neutralize CCN1 in vivo. By blocking
CCN1-promoted keratinocyte activation, the anti-CCN1 anti-
body treatment could reduce epidermal hyperplasia and
inﬂammation (Figures 2 and 3), the main psoriasis pathogen-
esis, consistent with the results from knocking down CCN1
expression using shRNA-expressing lentivirus vector in vivo
(Figure 4). These results further indicated that CCN1 has a
crucial role in psoriasis pathogenesis and might be a potent
target for psoriasis treatment.
Our present study suggests that ECM CCN1 also acts as an
enhancer in activated keratinocytes of forming a vicious cycle
of psoriatic lesions. In conclusion, our study shows that CCN1
is highly expressed in the lesional and non-lesional skin of
psoriasis patients and further triggers a cascade of keratino-
cyte activation, leading to the formation of the main
pathological features of psoriasis, including epidermal hyper-
plasia and inﬂammation. We provide conclusive original
evidence indicating that CCN1, as an ECM and pro-
inﬂammatory factor, is involved in the pathogenesis of
psoriasis and that blocking CCN1 may represent a potential
treatment strategy for psoriasis.
MATERIALS AND METHODS
Human skin specimens
Psoriasis patients with a dermatologist-conﬁrmed diagnosis of
chronic plaque psoriasis (15 females and 9 males; age range, 23–
56 years; mean age, 36.5 years) and normal volunteers (7 females
and 3 males; age range, 20–59 years; mean age, 40.5 years) were
recruited for the study. Psoriasis patients required a Psoriasis Area
Severity Index of at least 8 and a typical lesion of at least 1 cm in size
suitable for biopsy. One 4-mm biopsy from a lesional and an
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adjacent non-lesional site was collected from the psoriasis patients.
One 4-mm biopsy was obtained from each normal volunteer. The
target lesion and the surrounding 5-cm area were not treated with
any medicated topical formulation for at least 2 weeks before the
biopsy. The experiments were performed in accordance with the
Declaration of Helsinki Principles, and the study protocol and the
informed consent form were approved by the Independent Ethics
Committee of Shanghai Jiao Tong University Afﬁliated Ninth People’s
Hospital. Written informed consent was obtained from all patients.
RNAi lentivirus system
The pLVX-shRNA2 plasmid was extensively modiﬁed to carry a
cytomegalovirus promoter driving the expression of Zs Green1 and
the mouse U6 promoter with downstream restriction sites (BamHI
and EcoRI) to allow the efﬁcient introduction of oligonucleotides
encoding shRNA (Supplementary Table S1 online). The sequence of
shRNA targeting CCN1 was designed online (http://www.broad
institute.org/rnai/public/seq/search).
pLVX-iCCN1 and packaging vectors (pMD2.G and psPAX2) were
co-transfected into HEK293T cells. Titers were determined by
infecting HEK293T cells as described (Watson et al., 2002;
Rubinson et al., 2003).
Mice
Female BALB/c mice (8–11 weeks old) were purchased from the
Shanghai Laboratory Animal Center, Chinese Academy of Sciences,
Shanghai, China. All experiments were performed according to the
Animal Care and Use Committee guidelines of Shanghai Jiao Tong
University School of Medicine, Shanghai, China.
IL-23-induced psoriasis-like mice
The ears of the mice were injected with 20 μl of phosphate-buffered
saline containing 1 μg recombinant mouse IL-23 (eBioscience, San
Diego, CA) or BSA intradermally for 6 consecutive days (Chan et al.,
2006; Rizzo et al., 2011). Ear thickness was measured at the center of
the ears using a Vernier caliper. For the lentivirus transfection
experiment, 2×106 lentivirus particles (20 μl) were injected
intradermally into the mouse ears. After 3 days, the mice were
treated with IL-23 every day for 6 days.
IMQ-induced psoriasis-like mice
The mice received a daily topical dose of 62.5mg of a commercially
available IMQ cream (5%) (Aldara; 3M Pharmaceutical, St Paul,
MN) on the shaved back, translating into a daily dose of 3.125mg
of the active compound. The control mice were treated similarly
with Vaseline (Vaseline Lanette cream, Fagron, Rotterdam, the
Netherlands).
For lentivirus transfection in vivo, 5× 106 lentivirus
particles (100 μl) were injected intradermally into the back skin of
mice. After 3 days, the mice were treated with IMQ every day for
16 days.
For the antibody treatment, on day 2 of the IMQ treatment,
two groups of mice were administered anti-CCN1 mAb 093G9
generated in our laboratory or control IgG1 (Millipore, Billerica,
MA) at a dose of 200 μg day−1 intraperitoneally, according to
previous studies (Lin et al., 2012). On day 16, all mice were killed
and skin specimens were collected and inspected.
Cell culture
Primary cultured normal human keratinocytes were purchased from
PromoCell (Heidelberg, Germany). Cells were cultured in a
PromoCell Growth Media Kit (containing 0.004ml ml−1 bovine
pituitary extract, 0.125 μgml− 1 epidermal growth factor, and 5
μg ml−1 insulin) in a humidiﬁed 5% CO2 incubator. After 80%
conﬂuence was reached, the cells were passaged using a Detach Kit
(PromoCell).
Statistical analysis
All experiments were performed in triplicate. The results are
expressed as means± SD. Between-group differences were deter-
mined by analysis of variance, and comparisons between two groups
were performed with Tukey–Kramer post-test using GraphPad
Prism5.0 (GraphPad Software, San Diego, CA). For the human study,
statistical signiﬁcance was determined with Mann–Whitney U-test.
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